Lilly competitor fails to win FDA backing for diabetes treatment
AstraZeneca Plc didn’t receive U.S. approval for a new diabetes treatment that combines two of its existing drugs. The combination would have competed with Glyxambi from Lilly.
Health Care
Articles
Pence awards $3.5M contract to anti-abortion charity group
Gov. Mike Pence cited the successes of a $1 million pilot program as reason for granting a new $3.5 million contract to Real Alternatives, a Pennsylvania-based charity.
Indiana Blood Center names new chief executive
Long-time health care executive Charles C. Miraglia was picked by the center’s board of directors to replace interim CEO Dan A. Waxman, who has been in that position since January.
Cook executive, daughter die in plane crash
William S. Gibbons Jr., Cook's vice president of of global engineering, and his 15-year-old daughter, Abbey, were killed when the plane crashed into Buffalo Mountain in eastern Tennessee.
UPDATE: Lilly halts work on potential blockbuster cholesterol drug
Eli Lilly shares plunged nearly 10 percent Monday morning after it said it would stop development of evacetrapib, an experimental cholesterol drug with blockbuster potential.
Lilly expands China drug partnership in growing cancer market
Suzhou, China-based Innovent could receive payments totaling more than $1 billion if the cancer products it develops with Lilly reach certain milestones.
Lilly to add 50 employees at R&D center in New York
The drugmaker is trying to beef up its work on using the immune system to fight cancer. Indianapolis will remain Lilly’s main hub for research and development.
Novel approach to Alzheimer’s care set for Midwestern rollout
Dr. Malaz Boustani leads a 26-person team at Eskenazi Health that is showing the group's approach to health care can improve the mental health of both dementia patients and their care givers.
Nurse-unionization efforts stall at IU Health
Five months after it expected to hold an election, the union trying to organize nurses at Indiana University Health’s downtown hospitals doesn’t even have a projected date for a vote.
IU researchers develop suicide-prediction tool
Researchers at the Indiana University School of Medicine think they have found a way to predict possible suicides using blood tests and questionnaires on tablet computers.
Hospitals back on construction spree
Health care providers say they can’t attract patients tomorrow with facilities from yesterday. So they are scrambling to erect new structures that are more convenient.
Puerto Rico plans new corporate tax to replace excise levy
Puerto Rico officials are looking to replace an expiring tax with a new levy to draw much-needed revenue from the world’s best-selling medications while seeking to avoid driving U.S. manufacturers such as Eli Lilly and Co. from the commonwealth.
IU to receive up to $46M for effort to boost patient care
The university will lead a consortium of eight institutions that will use the money to create a system of coaches embedded in medical practices.
Settlement clears way for Lilly to launch once-a-day insulin
The settlement with France-based Sanofi SA clears up uncertainty over a drug that could rack up more than $1 billion in sales by 2020, according to Wall Street analysts.
Applications to Marian medical school keep rising
With the number of applications to Marian’s College of Osteopathic Medicine running twice as high as initially expected, school leaders say they are confident Marian can help reduce a looming physician shortage in Indiana.
Ball State trustees approve formation of College of Health
The new college's academic programs would include athletic training, nursing, speech pathology and psychology.
Purdue’s Chao Center regains drug, slashes $360-per-pill price
An Indiana not-for-profit has dropped the price of a drug for multi-drug resistant tuberculosis roughly 90 percent after re-acquiring rights to the medicine from Rodelis Therapeutics.
Lilly’s heart study sets up showdown with Novo’s Victoza
Unprecedented results from a cardiovascular study on a diabetes medicine sold by Eli Lilly and Co. turns up the pressure on rival Novo Nordisk, which will release data from a similar study on its competing drug next year.
Group urges Dems to tackle pharmaceutical prices
Pharmaceutical industry members are likely to dislike the proposal, which would require them disclose how much they spend on research and development, production, and sales and marketing.
Jardiance study lifts Lilly shares to 15-year high
Eli Lilly shares soared Thursday after study results showed Jardiance sharply reduced chances of dying in diabetic patients at high risk of heart complications. The study prompted at least one analyst to predict the drug could bring in billions of dollars by the end of the decade.